Travere Therapeutics, Inc. (TVTX): A Bull Case Theory

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. 7 Best Dialysis and Kidney Disease Stocks to Buy yezry/Shutterstock.com Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lea ...